Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24399-24411

  Feng, Dan ^a   Ma, Yanju ^a   Liu, Jing ^a   Xu, Ling ^a   Zhang, Ye ^a   Qu, Jinglei ^a   Liu, Yunpeng ^a   Qu, Xiujuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Cbl b; EGFR; ERK; Gastric cancer; PI3k Akt

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; OPTICAL DENSITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; STOMACH CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUOROURACIL; HUMANS; MITOCHONDRIA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84890527263     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224399     Document Type: Article

References (32)

1. Cervantes, A.; Rosello, S.; Roda, D.; Rodriguez-Braun, E. The treatment of advanced gastric cancer: Current strategies and future perspectives. Ann. Oncol. 2008, 19, v103-v107.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
3. Longley, D.; Harkin, D.; Johnston, P. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3, 330-338.
4. Boeckx, C.; Baay, M.; Wouters, A.; Specenier, P.; Vermorken, J.B.; Peeters, M.; Lardon, F. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance. Oncologist 2013, 18, 850-864.
5. Kim, J.W.; Kim, H.P.; Im, S.A.; Kang, S.; Hur, H.S.; Yoon, Y.K.; Oh, D.Y.; Kim, J.H.; Lee, D.S.; Kim, T.Y.; et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008, 272, 296-306.
6. Okabe, T.; Okamoto, I.; Tsukioka, S.; Uchida, J.; Iwasa, T.; Yoshida, T.; Hatashita, E.; Yamada, Y.; Satoh, T.; Tamura, K.; et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: Role of gefitinib-induced down-regulation of thymidylate synthase. Mol. Cancer Ther. 2008, 7, 599-606.
7. Hsu, C.; Gao, M.; Chen, C.; Yeh, P.; Cheng, A. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 2005, 68, 538-547.
8. Nozawa, H.; Tadakuma, T.; Ono, T.; Sato, M.; Hiroi, S.; Masumoto, K.; Sato, Y. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci. 2006, 97, 1115-1124.
9. Wu, X.; Deng, Y.; Wang, G.; Tao, K. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J. Surg. Res. 2007, 138, 56-63.
10. Van Schaeybroeck, S.; Karaiskou-McCaul, A.; Kelly, D.; Longley, D.; Galligan, L.; van Cutsem, E.; Johnston, P. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin. Cancer Res. 2005, 11, 7480-7489.
11. Komoto, M.; Nakata, B.; Nishii, T.; Kawajiri, H.; Shinto, O.; Amano, R.; Yamada, N.; Yashiro, M.; Hirakawa, K. In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci. 2010, 101, 468-473.
12. Mohapatra, B.; Ahmad, G.; Nadeau, S.; Zutshi, N.; An, W.; Scheffe, S.; Dong, L.; Feng, D.; Goetz, B.; Arya, P.; et al. Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. BBA Mol. Cell Res. 2013, 1833, 122-139.
13. Komander, D. The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 2009, 37, 937-953.
14. Dikic, I.; Wakatsuki, S.; Walters, K. Ubiquitin-binding domains-From structures to functions. Nat. Rev. Mol. Cell Biol. 2009, 10, 659-671.
15. Duan, L.; Reddi, A.L.; Ghosh, A.; Dimri, M.; Band, H. The Cbl family and other ubiquitin ligases: Destructive forces in control of antigen receptor signaling. Immunity 2004, 21, 7-17.
16. Fang, D.; Wang, H.; Fang, N.; Altman, Y.; Elly, C.; Liu, Y. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J. Biol. Chem. 2001, 276, 4872-4878.
17. Fang, D.; Liu, Y.C. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat. Immunol. 2001, 2, 870-875.
18. Zhang, R.; Zhang, N.; Mueller, D.L. Casitas B-lineage lymphoma b inhibits antigen recognition and slows cell cycle progression at late times during CD4+ T cell clonal expansion. J. Immunol. 2008, 181, 5331-5339.
19. Qu, X.; Zhang, Y.; Li, Y.; Hu, X.; Xu, Y.; Xu, L.; Hou, K.; Sada, K.; Liu, Y. Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals. FEBS Lett. 2009, 583, 2255-2262.
20. Qu, X.; Li, Y.; Liu, J.; Xu, L.; Zhang, Y.; Hu, X.; Hou, K.; Liu, Y. Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation. Mol. Cell. Biochem. 2010, 340, 107-114.
21. Li, Y.; Qu, X.; Qu, J.; Zhang, Y.; Liu, J.; Teng, Y.; Hu, X.; Hou, K.; Liu, Y. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009, 284, 208-215.
22. Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; de Toni, E.N.; Schwarz, B.; Graeb, C.; Eichhorn, M.E.; Jauch, K.W.; et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling. Oncogene 2008, 27, 7212-7222.
23. Pu, Y.; Hsieh, M.; Wang, C.; Liu, G.; Huang, C.; Lin, C.; Guan, J.; Lin, S.; Hour, T. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem. Pharmacol. 2006, 71, 751-760.
24. Bu, X.; Jia, F.; Wang, W.; Guo, X.; Wu, M.; Wei, L. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer 2007, 7, 208.
25. Qin, L.; Zhang, X.; Zhang, L.; Feng, Y.; Weng, G.X.; Li, M.Z.; Kong, Q.L.; Qian, C.N.; Zeng, Y.X.; Zeng, M.S.; et al. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 2008, 371, 531-535.
26. Xu, L.; Qu, X.; Zhang, Y.; Hu, X.; Yang, X.; Hou, K.; Teng, Y.; Zhang, J.; Sada, K.; Liu, Y. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 2009, 583, 943-948.
27. Wang, Y.; Chen, Z.; Bergmann, A. Regulation of EGFR and Notch signaling by distinct isoforms of D-cbl during Drosophila development. Dev. Biol. 2010, 342, 1-10.
28. Tan, Y.; Krishnaswamy, S.; Nandi, S.; Kanteti, R.; Vora, S.; Onel, K.; Hasina, R.; Lo, F.; El-Hashani, E.; Cervantes, G.; et al. CBL is frequently altered in lung cancers: Its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 2010, 5, e8972.
29. Vivanco, I.; Rohle, D.; Versele, M.; Iwanami, A.; Kuga, D.; Oldrini, B.; Tanaka, K.; Dang, J.; Kubek, S.; Palaskas, N.; et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. USA 2010, 107, 6459-6464.
30. Feng, Y.; Tsao, C.; Wu, C.; Chang, J.; Lu, P.; Yeh, K.; Shieh, G.; Shiau, A.; Lee, J. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci. 2010, 101, 2033-2038.
31. Ettenberg, S.; Keane, M.; Nau, M.; Frankel, M.; Wang, L.; Pierce, J.; Lipkowitz, S. cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 1999, 18, 1855-1866.
32. Ahsan, A.; Hiniker, S.; Ramanand, S.; Nyati, S.; Hegde, A.; Helman, A.; Menawat, R.; Bhojani, M.; Lawrence, T.; Nyati, M. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 2010, 70, 2862-2869.